bardoxolone methyl (RTA 402) / Reata, Kyowa Kirin, Biogen 
Welcome,         Profile    Billing    Logout  

4 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
bardoxolone methyl (RTA 402) / Kyowa Kirin, Biogen
2016-004365-16: An open-label study to learn if Bardoxolone Methyl is safe in the long-term in patients with pulmonary hypertension. Estudio abierto para comprobar si bardoxolona metilo es seguro a largo plazo en pacientes con hipertensión pulmonar

Ongoing
3
414
Europe
Bardoxolone Methyl, RTA 402, Capsule, hard
Reata Pharmaceuticals, Inc., Reata Pharmaceuticals, Inc.
Pulmonary Hypertension Hipertensión pulmonar, Raised blood pressure in the arteries that supply the lungs Aumento de la presión arterial en las arterias que suministran los pulmones, Diseases [C] - Cardiovascular Diseases [C14]
 
 
AYAME, NCT03550443: A Phase 3 Study of Bardoxolone Methyl in Patients With Diabetic Kidney Disease; Study

Terminated
3
1323
Japan
Bardoxolone methyl, RTA 402, Placebo
Kyowa Kirin Co., Ltd.
Diabetic Kidney Disease
11/22
07/23
EAGLE, NCT03749447 / 2018-003253-24: An Extended Access Program for Bardoxolone Methyl in Patients With CKD

Terminated
3
270
Europe, Japan, US, RoW
Bardoxolone methyl, RTA 402
Reata, a wholly owned subsidiary of Biogen, Reata Pharmaceuticals, Inc.
Chronic Kidney Diseases, Alport Syndrome, Autosomal Dominant Polycystic Kidney
08/23
08/23
FALCON, NCT03918447 / 2018-004651-20: A Trial of Bardoxolone Methyl in Patients With ADPKD -

Terminated
3
667
Europe, Japan, US, RoW
Bardoxolone methyl oral capsule, RTA 402, Placebo oral capsule
Reata, a wholly owned subsidiary of Biogen, Reata Pharmaceuticals, Inc., REATA PHARMACEUTICALS, INC
Autosomal Dominant Polycystic Kidney, ADPKD
08/23
08/23

Download Options